Listed pharmaceutical entity Shilpa Medicare on Monday informed the exchanges that its subsidiary Shilpa Biologicals (SBPL) has received a NoC from RCGM, Dept of Biotechnology to approach the Drugs Controller General of India (DCGI) to conduct clinical studies for its Biosimilar Aflibercept.
